CTOs on the Move

LKC Technologies

www.lkc.com

 
LKC Technologies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lkc.com
  • 2 Professional Dr Ste 222
    Gaithersburg, MD USA 20879
  • Phone: 301.840.1992

Executives

Name Title Contact Details

Similar Companies

NuGEN Technologies

NuGEN Technologies is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Emrn Inc

Emrn Inc is a Le Gardeur, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Katalyst Surgical

Katalyst Surgical is the industry leader in ophthalmic surgical instruments. Our experienced team has over 40 years of design, manufacturing, and quality control of ophthalmic surgical products. It is our goal to provide superior service paired with high quality ophthalmic products at a cost saving to our customers. We stand by our company-wide policy that the customer is always right... By continually gathering customer feedback and working with our highly skilled professional team, Katalyst Surgical continues to deliver unmatched ophthalmic instruments while increasing our number of loyal customers. Katalyst Surgical is a premier research and development facility... Keeping up with cutting edge products and the changing industry has allowed us to serve our customers with 100% satisfaction Superior products within your budget... Your business is important to our team at Katalyst Surgical. Our goal is to offer superior products with premium customer service within your budget. Committed to our customers... We greatly appreciate your feedback on our ophthalmic surgical instruments and repair services.

Mobility Works

Mobility Works is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JenaValve

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.